Nanoparticles: A promising therapeutic approach in atherosclerosis

Current Drug Delivery

Volumn 7, Issue 4, 2010, Pages 303-311

  Antoniades, Charalambos ^a,b   Psarros, Costantinos ^a   Tousoulis, Dimitris ^a   Bakogiannis, Constantinos ^a   Shirodaria, Cheerag ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; Drug delivery systems; Folates; Inflammation; Nanoparticles

Indexed keywords

COPOLYMER; FULLERENE; FUMAGILLIN; GADOLINIUM; GLUCOCORTICOID; IMMUNOGLOBULIN; LIPOSOME; MACROGOL; NANOCOMPOSITE; NANOPARTICLE; POLYURETHAN; PROSTAGLANDIN A1; PROTEIN DERIVATIVE; STREPTAVIDIN; VITRONECTIN RECEPTOR;

ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; IMAGING; NANOTOXICOLOGY; PRIORITY JOURNAL;

CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHYSICOCHEMICAL PHENOMENA;

EID: 77958498200     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110793360586     Document Type: Article

References (69)

1. Mackay, J.; Mensah, G. Atlas of Heart Disease and Stroke; World Health Organization (WHO) Press: Geneva, 2004.
2. Tousoulis, D.; Antoniades, C.; Stefanadis, C. Assessing inflammatory status in cardiovascular disease. Heart, 2007, 93(8), 1001-1007.
3. Ridker, P. M.; Hennekens, C. H.; Buring, J. E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000, 342(12), 836-843.
4. Antoniades, C.; Antonopoulos, A. S.; Bendall, J. K.; Channon, K. M. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr. Pharm. Des., 2009, 15(3), 329-342.
5. Antoniades, C.; Tousoulis, D.; Tentolouris, C.; Toutouzas, P.; Stefanadis, C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz, 2003, 28(7), 628-638.
6. Antoniades, C.; Shirodaria, C.; Warrick, N.; Cai, S.; de Bono, J.; Lee, J.; Leeson, P.; Neubauer, S.; Ratnatunga, C.; Pillai, R.; Refsum, H.; Channon, K. M. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation, 2006, 114(11), 1193-1201.
7. Shirodaria, C.; Antoniades, C.; Lee, J.; Jackson, C. E.; Robson, M. D.; Francis, J. M.; Moat, S. J.; Ratnatunga, C.; Pillai, R.; Refsum, H.; Neubauer, S.; Channon, K. M. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation, 2007, 115(17), 2262-2270.
8. Hadjichristidis, N.; Pitsikalis, M.; Pispas, S.; Iatrou, H. Polymers with complex architecture by living anionic polymerization. Chem. Rev., 2001, 101(12), 3747-3792.
9. Discher, D. E.; Eisenberg, A. Polymer vesicles. Science, 2002, 297(5583), 967-973.
10. Wickline, S. A.; Neubauer, A. M.; Winter, P. M.; Caruthers, S. D.; Lanza, G. M. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging, 2007, 25(4), 667-680.
11. Ding, B. S.; Dziubla, T.; Shuvaev, V. V.; Muro, S.; Muzykantov, V. R. Advanced drug delivery systems that target the vascular endothelium. Mol. Interv., 2006, 6(2), 98-112.
12. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83(5), 761-769.
13. Ahmed, F.; Discher, D. E. Self-porating polymersomes of PEGPLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J. Control Release, 2004, 96(1), 37-53.
14. Photos, P. J.; Bacakova, L.; Discher, B.; Bates, F. S.; Discher, D. E. Polymer vesicles in vivo: correlations with PEG molecular weight. J. Control Release, 2003, 90(3), 323-334.
15. Moghimi, S. M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid. Res., 2003, 42(6), 463-478.
16. Rosler, A.; Vandermeulen, G. W.; Klok, H. A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv. Drug. Deliv. Rev., 2001, 53(1), 95-108.
17. Discher, B. M.; Won, Y. Y.; Ege, D. S.; Lee, J. C.; Bates, F. S.; Discher, D. E.; Hammer, D. A. Polymersomes: tough vesicles made from diblock copolymers. Science, 1999, 284(5417), 1143-1146.
18. Muro, S.; Koval, M.; Muzykantov, V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr. Vasc. Pharmacol., 2004, 2(3), 281-299.
19. Everts, M.; Kok, R. J.; Asgeirsdottir, S. A.; Melgert, B. N.; Moolenaar, T. J.; Koning, G. A.; van Luyn, M. J.; Meijer, D. K.; Molema, G. Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J. Immunol., 2002, 168(2), 883-889.
20. Kessner, S.; Krause, A.; Rothe, U.; Bendas, G. Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells. Biochim. Biophys. Acta., 2001, 1514(2), 177-190.
21. Muro, S.; Gajewski, C.; Koval, M.; Muzykantov, V. R. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood, 2005, 105(2), 650-658.
22. Eugenin, E. A.; Gamss, R.; Buckner, C.; Buono, D.; Klein, R. S.; Schoenbaum, E. E.; Calderon, T. M.; Berman, J. W. Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J. Leukoc. Biol., 2006, 79(3), 444-452.
23. Hopkins, A. M.; Baird, A. W.; Nusrat, A. ICAM-1: targeted docking for exogenous as well as endogenous ligands. Adv. Drug. Deliv. Rev., 2004, 56(6), 763-778.
24. Mulder, W. J.; Strijkers, G. J.; Briley-Saboe, K. C.; Frias, J. C.; Aguinaldo, J. G.; Vucic, E.; Amirbekian, V.; Tang, C.; Chin, P. T.; Nicolay, K.; Fayad, Z. A. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med., 2007, 58(6), 1164-1170.
25. Briley-Saebo, K. C.; Shaw, P. X.; Mulder, W. J.; Choi, S. H.; Vucic, E.; Aguinaldo, J. G.; Witztum, J. L.; Fuster, V.; Tsimikas, S.; Fayad, Z. A. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation, 2008, 117(25), 3206-3215.
26. Chnari, E.; Lari, H. B.; Tian, L.; Uhrich, K. E.; Moghe, P. V.Nanoscale anionic macromolecules for selective retention of lowdensity lipoproteins. Biomaterials, 2005, 26(17), 3749-3758.
27. Winter, P. M.; Neubauer, A. M.; Caruthers, S. D.; Harris, T. D.; Robertson, J. D.; Williams, T. A.; Schmieder, A. H.; Hu, G.; Allen, J. S.; Lacy, E. K.; Zhang, H.; Wickline, S. A.; Lanza, G. M. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2006, 26(9), 2103-2109.
28. Zhang, Y.; Yeh, J. R.; Mara, A.; Ju, R.; Hines, J. F.; Cirone, P.; Griesbach, H. L.; Schneider, I.; Slusarski, D. C.; Holley, S. A.; Crews, C. M. A chemical and genetic approach to the mode of action of fumagillin. Chem. Biol., 2006, 13(9), 1001-1009.
29. Winter, P. M.; Caruthers, S. D.; Kassner, A.; Harris, T. D.; Chinen, L. K.; Allen, J. S.; Lacy, E. K.; Zhang, H.; Robertson, J. D.; Wickline, S. A.; Lanza, G. M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 2003, 63(18), 5838-5843.
30. Winter, P. M.; Caruthers, S. D.; Yu, X.; Song, S. K.; Chen, J.; Miller, B.; Bulte, J. W.; Robertson, J. D.; Gaffney, P. J.; Wickline, S. A.; Lanza, G. M. Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med., 2003, 50(2), 411-416.
31. Winter, P. M.; Morawski, A. M.; Caruthers, S. D.; Fuhrhop, R. W.; Zhang, H.; Williams, T. A.; Allen, J. S.; Lacy, E. K.; Robertson, J. D.; Lanza, G. M.; Wickline, S. A. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrintargeted nanoparticles. Circulation, 2003, 108(18), 2270-2274.
32. Winter, P. M.; Caruthers, S. D.; Zhang, H.; Williams, T. A.; Wickline, S. A.; Lanza, G. M. Antiangiogenic synergism of integrintargeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging, 2008, 1(5), 624-634.
33. Shuvaev, V. V.; Dziubla, T.; Wiewrodt, R.; Muzykantov, V. R. Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress. Methods Mol. Biol., 2004, 283, 3-19.
34. Wiewrodt, R.; Thomas, A. P.; Cipelletti, L.; Christofidou-Solomidou, M.; Weitz, D. A.; Feinstein, S. I.; Schaffer, D.; Albelda, S. M.; Koval, M.; Muzykantov, V. R. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood, 2002, 99(3), 912-922.
35. Muzykantov, V. R.; Christofidou-Solomidou, M.; Balyasnikova, I.; Harshaw, D. W.; Schultz, L.; Fisher, A. B.; Albelda, S. M. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl. Acad. Sci. U S A, 1999, 96(5), 2379-2384.
36. Atochina, E. N.; Balyasnikova, I. V.; Danilov, S. M.; Granger, D. N.; Fisher, A. B.; Muzykantov, V. R. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am. J. Physiol.,1998, 275(4 Pt 1), L806-817.
37. Christofidou-Solomidou, M.; Scherpereel, A.; Wiewrodt, R.; Ng, K.; Sweitzer, T.; Arguiri, E.; Shuvaev, V.; Solomides, C. C.; Albelda, S. M.; Muzykantov, V. R. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am. J. Physiol. Lung Cell. Mol. Physiol., 2003, 285(2), L283-292.
38. Sweitzer, T. D.; Thomas, A. P.; Wiewrodt, R.; Nakada, M. T.; Branco, F.; Muzykantov, V. R. PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic. Bio. Med., 2003, 34(8), 1035-1046.
39. Kozower, B. D.; Christofidou-Solomidou, M.; Sweitzer, T. D.; Muro, S.; Buerk, D. G.; Solomides, C. C.; Albelda, S. M.; Patterson, G. A.; Muzykantov, V. R. Immunotargeting of catalase to the pulmonary endothelium alleviaes oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol., 2003, 21(4), 392-398.
40. Chabot, F.; Mitchell, J. A.; Gutteridge, J. M.; Evans, T. W. Reactive oxygen species in acute lung injury. Eur. Respir. J., 1998, 11(3), 745-757.
41. Fox, R. B.; Hoidal, J. R.; Brown, D. M.; Repine, J. E. Pulmonary inflammation due to oxygen toxicity: involvement of chemotactic factors and polymorphonuclear leukocytes. Am. Rev. Respir. Dis., 1981, 123(5), 521-523.
42. Leff, J. A.; Parsons, P. E.; Day, C. E.; Taniguchi, N.; Jochum, M.; Fritz, H.; Moore, F. A.; Moore, E. E.; McCord, J. M.; Repine, J. E. Serum antioxidants as predictors of adult respiratory distress syndrome in patients with sepsis. Lancet, 1993, 341(8848), 777-780.
43. Simone, E. A.; Dziubla, T. D.; Discher, D. E.; Muzykantov, V. R. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules, 2009, 10(6), 1324-1330.
44. Muzykantov, V. R.; Atochina, E. N.; Ischiropoulos, H.; Danilov, S. M.; Fisher, A. B. Immunotargeting of antioxidant enzyme to the pulmonary endothelium. Proc. Natl. Acad. Sci. U S A, 1996, 93(11), 5213-5218.
45. Murciano, J. C.; Muro, S.; Koniaris, L.; Christofidou-Solomidou, M.; Harshaw, D. W.; Albelda, S. M.; Granger, D. N.; Cines, D. B.; Muzykantov, V. R. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood, 2003, 101(10), 3977-3984.
46. Schwendener, R. A. Liposomes in biology and medicine. Adv. Exp. Med. Biol., 2007, 620, 117-128.
47. Christian, D. A.; Cai, S.; Bowen, D. M.; Kim, Y.; Pajerowski, J. D.; Discher, D. E. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm., 2009, 71(3), 463-474.
48. Zalipsky, S.; Qazen, M.; Walker, J. A., 2nd; Mullah, N.; Quinn, Y. P.; Huang, S. K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem., 1999, 10(5), 703-707.
49. Bergstrand, N.; Arfvidsson, M. C.; Kim, J. M.; Thompson, D. H.; Edwards, K. Interactions between pH-sensitive liposomes and model membranes. Biophys. Chem., 2003, 104(1), 361-379.
50. Shin, J.; Shum, P.; Thompson, D. H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control Release, 2003, 91(1-2), 187-200.
51. Lobatto, M. E.; Silvera, S.; Vucic, E.; Mani, V.; Banciu, M.; Mulder, W. J. Novel nanomedicine for anti-inflammatory therapy of atheroschlerosis monitored by multimodality imaging. Proc. Intl. Soc. Mag. Reson. Med., 2008, 16(Suppl), 12.
52. Rensen, P. C.; Gras, J. C.; Lindfors, E. K.; van Dijk, K. W.; Jukema, J. W.; van Berkel, T. J.; Biessen, E. A. Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A. Curr. Drug. Discov. Technol., 2006, 3(2), 135-144.
53. Antoniades, C.; Antonopoulos, A. S.; Tousoulis, D.; Marinou, K.; Stefanadis, C. Homocysteine d coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur. Heart. J., 2009, 30(1), 6-15.
54. Juillerat-Jeanneret, L.; Schmitt, F. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med. Res. Rev., 2007, 27(4), 574-590.
55. Mainardes, R. M.; Silva, L. P. Drug delivery systems: past, present, and future. Curr. Drug. Targets., 2004, 5(5), 449-455.
56. Vakhrusheva, T.; Panasenko, O. Chondroitin 6-sulfate and dextran sulfate promote hypochlorite-induced peroxidation of phosphatidylcholine liposomes. Chem. Phys. Lipids, 2006, 140(1-2), 18-27.
57. Homem de Bittencourt, P. I., Jr.; Lagranha, D. J.; Maslinkiewicz, A.; Senna, S. M.; Tavares, A. M.; Baldissera, L. P.; Janner, D. R.; Peralta, J. S.; Bock, P. M.; Gutierrez, L. L.; Scola, G.; Heck, T. G.; Krause, M. S.; Cruz, L. A.; Abdalla, D. S.; Lagranha, C. J.; Lima, T.; Curi, R. LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis, 2007, 193(2), 245-258.
58. Rotmans, J. I.; Heyligers, J. M.; Verhagen, H. J.; Velema, E.; Nagtegaal, M. M.; de Kleijn, D. P.; de Groot, F. G.; Stroes, E. S.; Pasterkamp, G. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation, 2005, 112(1), 12-18.
59. Jordan, S. W.; Chaikof, E. L. Novel thromboresistant materials. J. Vasc. Surg., 2007, 45 (Suppl A), A104-115.
60. Wilson, J. T.; Cui, W.; Sun, X. L.; Tucker-Burden, C.; Weber, C.J.; Chaikof, E. L. In vivo biocompatibility and stability of a substrate-supported polymerizable membrane-mimetic film. Biomaterials, 2007, 28(4), 609-617.
61. Maeda, R.; Noiri, E.; Isobe, H.; Homma, T.; Tanaka, T.; Negishi, K.; Doi, K.; Fujita, T.; Nakamura, E. A. water-soluble fullerene vesicle alleviates angiotensin II-induced oxidative stress in human umbilical venous endothelial cells. Hypertens. Res., 2008, 31(1), 141-151.
62. Walker, V. G.; Li, Z.; Hulderman, T.; Schwegler-Berry, D.; Kashon, M. L.; Simeonova, P. P. Potential in vitro effects of carbon nanotubes on human aortic endothelial cells. Toxicol. Appl. Pharmacol., 2009, 236(3), 319-328.
63. Niwa, Y.; Iwai, N. Nanomaterials induce oxidized low-density lipoprotein cellular uptake in macrophages and platelet aggregation. Circ. J., 2007, 71(3), 437-444.
64. Lanza, G. M.; Wallace, K. D.; Scott, M. J.; Cacheris, W. P.; Abendschein, D. R.; Christy, D. H.; Sharkey, A. M.; Miller, J. G.; Gaffney, P. J.; Wickline, S. A. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation, 1996, 94(12), 3334-3340.
65. Schmitz, S. A.; Coupland, S. E.; Gust, R.; Winterhalter, S.; Wagner, S.; Kresse, M.; Semmler, W.; Wolf, K. J. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol., 2000, 35(8), 460-471.
66. Nel, A.; Xia, T.; Madler, L.; Li, N. Toxic potential of materials at the nanolevel. Science, 2006, 311(5761), 622-627.
67. Magrez, A.; Kasas, S.; Salicio, V.; Pasquier, N.; Seo, J. W.; Celio, M.; Catsicas, S.; Schwaller, B.; Forro, L. Cellular toxicity of carbon-based nanomaterials. Nano. Lett., 2006, 6(6), 1121-1125.
68. Holsapple, M. P.; Farland, W. H.; Landry, T. D.; Monteiro-Riviere, N. A.; Carter, J. M.; Walker, N. J.; Thomas, K. V. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs. Toxicol. Sci., 2005, 88(1), 12-17.
69. Geiser, M.; Rothen-Rutishauser, B.; Kapp, N.; Schurch, S.; Kreyling, W.; Schulz, H.; Semmler, M.; Im Hof, V.; Heyder, J.; Gehr, P. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health. Perspect., 2005, 113(11), 1555-1560.